A chimeric antigen receptor targeting and activating T cells, mesenchymal cells and their applications
By designing a chimeric antigen receptor that targets and activates T cells to bind to mesenchymal cells, precise intervention on overactivated T cells is achieved, solving the treatment challenges of aGVHD and CRS, improving treatment efficiency and safety, and expanding the scope of application.
Patent Information
- Application Number
- CN202611470653.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-21
- Publication Date
- 2026-11-17
AI Technical Summary
In existing technologies, patients undergoing allogeneic hematopoietic stem cell transplantation are prone to acute graft-versus-host disease (aGVHD), and CAR-T therapy suffers from cytokine release syndrome (CRS), which severely restricts its clinical application. Traditional mesenchymal cells lack targeting capabilities and have uncertain immunomodulatory effects, making them difficult to treat effectively.
We designed a chimeric antigen receptor (CAR) that targets activated T cells, using OX40 as a marker molecule for activated T cells. By structurally targeting OX40 with the CAR, we can precisely intervene in over- or abnormally activated T cells and combine it with mesenchymal cells (MSCs) for immune regulation, thereby achieving specific targeted regulation of pathologically activated T cells.
It increases the local concentration at aGVHD and CRS lesions, enhances treatment efficiency, selectively inhibits pathogenic T cells, reduces side effects, preserves normal immune function, and is applicable to a variety of T cell-mediated immunopathological processes, with broad application potential.
Smart Images

Figure CN123106924A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of immunotherapy technology, and particularly relates to a chimeric antigen receptor that targets and activates T cells, mesenchymal cells, and their applications. Background Technology
[0002] Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective, and sometimes the only, curative treatment for benign and malignant diseases such as hematological malignancies and hematopoietic injury. However, transplant patients are prone to acute graft-versus-host disease (aGVHD). aGVHD is the leading cause of non-relapse mortality in allo-HSCT, severely limiting the efficacy of transplantation. Donor T cell activation is a key step in the development of aGVHD. Activated T cells secrete cytokines and directly attack target organs such as the recipient's skin, gastrointestinal tract, and liver, mediating the occurrence of aGVHD. Glucocorticoids, as the standard first-line treatment for aGVHD, are effective in only about half of patients, and long-term, high-dose systemic use of hormones increases the risk of opportunistic infections and relapse. There is a lack of effective treatments for hormone-resistant aGVHD. Therefore, the development of effective treatments for aGVHD is an urgent clinical need.
[0003] Chimeric antigen receptor T-cell (CAR-T) therapy is a revolutionary adoptive cellular immunotherapy strategy that has achieved significant efficacy in the clinical treatment of hematologic malignancies. However, CAR-T therapy is accompanied by serious toxic side effects during clinical application, among which cytokine release syndrome (CRS) is one of the most common and life-threatening complications, severely restricting the clinical promotion and application of CAR-T therapy. The occurrence of CRS is closely related to the overactivation of CAR-T cells in vivo. After CAR-T infusion, driven by activation signals that recognize target antigens, CAR-T cells can proliferate explosively in a short period of time, producing a large number of activated effector T cells. During this process, activated CAR-T cells and their recruited innate immune cells (including macrophages, monocytes, and neutrophils) secrete large amounts of pro-inflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and interleukin-1β (IL-1β), triggering a systemic inflammatory response. Clinical manifestations include persistent high fever, hypotension, and hypoxemia; in severe cases, it can progress to multiple organ dysfunction syndrome (MODS) and even lead to death. Current clinical interventions mainly include the use of IL-6 receptor antagonists (such as tocilizumab) and glucocorticoids. However, while these treatments suppress the inflammatory response, they inevitably impair the anti-tumor activity of CAR-T cells, resulting in a narrow therapeutic window and difficulty in guaranteeing clinical efficacy.
[0004] Mesenchymal stem cells (MSCs), as a type of adult stem cell with multipotent differentiation potential, have attracted much attention due to their low immunogenicity, high safety, wide availability from various tissues, ease of in vitro expansion, and powerful immunomodulatory functions. Their immunomodulatory effects are mainly achieved through direct contact with target cells to transmit inhibitory signals, secrete soluble factors, and alter the local metabolic microenvironment to regulate immune responses. Therefore, they are being explored for the treatment of immune-related diseases such as GVHD and CRS. On December 18, 2024, the U.S. Food and Drug Administration (FDA) approved the world's first mesenchymal cell product, Ryoncil, developed by Mesoblast, for the treatment of hormone-refractory aGVHD in pediatric patients. On January 2, 2025, the China National Medical Products Administration (NMPA) approved Amymetoxetine injection, developed by Platinum Biotech, for the treatment of hormone-refractory aGVHD primarily involving the gut. Meanwhile, research on using MSCs to treat CRS has been widely reported, with some already in clinical trials. However, traditional MSCs have significant limitations. First, MSCs exhibit significant cellular heterogeneity. MSCs from different donors and tissues show considerable heterogeneity in their proliferation, secretion, and immunomodulatory functions. Even MSCs from the same source show inconsistent and unstable therapeutic effects under different culture conditions and passages. Second, free MSCs lack targeting specific lesions or target cells, affecting their homing and local efficacy in vivo. Finally, the specific mechanisms of their immunomodulatory effects are not fully elucidated, and their response in complex pathological microenvironments is uncertain, thus limiting their clinical application. Summary of the Invention
[0005] In view of this, the purpose of this invention is to provide a chimeric antigen receptor that targets activated T cells. By utilizing the characteristic of OX40 as a marker molecule for activated T cells, and through CAR structure-specific targeting of OX40, it precisely intervenes in T cells in an over- or abnormally activated state, thereby maximizing the immunomodulatory potential of MSCs and providing a more targeted, homogeneous, and efficient novel cell therapy for the treatment of immune-related diseases such as GVHD, CRS, and autoimmune diseases.
[0006] Another object of the present invention is to provide a nucleic acid molecule.
[0007] Another object of the present invention is to provide a recombinant expression vector.
[0008] Another object of the present invention is to provide a mesenchymal cell.
[0009] Another object of the present invention is to provide a method for preparing the mesenchymal cells.
[0010] Another object of the present invention is to provide an application of the aforementioned mesenchymal cells.
[0011] Another object of the present invention is to provide a pharmaceutical composition.
[0012] To achieve the above-mentioned objectives, the present invention provides the following technical solution: This invention provides a chimeric antigen receptor that targets and activates T cells, comprising, from the N-terminus to the C-terminus, a signal peptide, an antigen recognition domain, a hinge region, a transmembrane domain, and an intracellular signal transduction domain; the amino acid sequence of the antigen recognition domain is shown in SEQ ID NO:2.
[0013] Preferably, the signal peptide includes the CD8α signal peptide.
[0014] Preferably, the coding sequence of the CD8α signal peptide is shown in SEQ ID NO:3, and the amino acid sequence is shown in SEQ ID NO:4.
[0015] Preferably, the coding sequence of the antigen recognition domain is shown in SEQ ID NO:1.
[0016] Preferably, the hinge region includes a CD8α hinge region, a CD28 hinge region, an IgG1 Fc hinge region, or an IgG4 Fc hinge region.
[0017] Preferably, the coding sequence of the CD8α hinge region is shown in SEQ ID NO:5, and the amino acid sequence is shown in SEQ ID NO:6.
[0018] Preferably, the IgG4 Fc hinge region includes a short IgG4 Fc hinge region, a medium IgG4 Fc hinge region, or a long IgG4 Fc hinge region.
[0019] Preferably, the coding sequence of the short IgG4 Fc hinge region is shown in SEQ ID NO:20, and the amino acid sequence is shown in SEQ ID NO:21.
[0020] Preferably, the coding sequence of the IgG4 Fc hinge region is shown in SEQ ID NO:22, and the amino acid sequence is shown in SEQ ID NO:23.
[0021] Preferably, the coding sequence of the long IgG4 Fc hinge region is shown in SEQ ID NO:24, and the amino acid sequence is shown in SEQ ID NO:25.
[0022] Preferably, the transmembrane domain includes a CD8α transmembrane domain, a CD28 transmembrane domain, a CD3ζ transmembrane domain, or a 4-1BB transmembrane domain.
[0023] Preferably, the coding sequence of the CD8α transmembrane domain is shown in SEQ ID NO:7, and the amino acid sequence is shown in SEQ ID NO:8.
[0024] Preferably, the intracellular signal transduction domain includes an activation domain and / or a co-stimulatory domain.
[0025] Preferably, the activation domain includes the CD3ζ activation domain.
[0026] Preferably, the coding sequence of the CD3ζ activation domain is shown in SEQ ID NO:11, and the amino acid sequence is shown in SEQ ID NO:12.
[0027] Preferably, the co-stimulatory domain includes one or more of the following: CD28 co-stimulatory domain, 4-1BB co-stimulatory domain, OX40 co-stimulatory domain, ICOS co-stimulatory domain, CD27 co-stimulatory domain, and CD40 co-stimulatory domain.
[0028] Preferably, the number of co-stimulatory domains is 1 to 3.
[0029] Preferably, the coding sequence of the 4-1BB co-stimulatory domain is shown in SEQ ID NO:9, and the amino acid sequence is shown in SEQ ID NO:10.
[0030] Preferably, the coding sequence of the CD28 co-stimulatory domain is shown in SEQ ID NO:26, and the amino acid sequence is shown in SEQ ID NO:27.
[0031] The present invention also provides a nucleic acid molecule that encodes the chimeric antigen receptor.
[0032] Preferably, the nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO:13.
[0033] The present invention also provides a recombinant expression vector comprising the nucleic acid molecule.
[0034] The present invention also provides a mesenchymal cell comprising the nucleic acid molecule or the recombinant expression vector.
[0035] The present invention also provides a method for preparing the mesenchymal cells, comprising: introducing the nucleic acid molecule or the recombinant expression vector into primitive mesenchymal cells to obtain the mesenchymal cells.
[0036] The present invention also provides the use of the mesenchymal cells described above in the preparation of products for the treatment and / or prevention of diseases related to abnormal or excessive activation of T cells.
[0037] Preferably, the T-cell abnormality or overactivation-related diseases include graft-versus-host disease, side effects caused by CAR-T therapy, autoimmune diseases, or organ transplant rejection.
[0038] Preferably, the side effects caused by the CAR-T therapy include cytokine release syndrome.
[0039] The present invention also provides a pharmaceutical composition comprising the mesenchymal cells and a pharmaceutically acceptable carrier.
[0040] The beneficial effects of this invention are: This invention provides a chimeric antigen receptor that targets activated T cells and mesenchymal cells expressing the chimeric antigen receptor. Utilizing the characteristic of OX40 as a marker molecule for activated T cells, the invention precisely intervenes in T cells in an over- or abnormally activated state by targeting OX40 through CAR structure-specific targeting, thereby maximizing the immunomodulatory potential of mesenchymal cells. This provides a novel cell therapy that is more targeted, homogeneous, and efficient for the treatment of immune-related diseases such as GVHD, CRS, and autoimmune diseases.
[0041] This invention achieves specific targeted regulation of pathologically activated T cells. OX40 is highly expressed only on the surface of activated T cells, while it is not expressed or is expressed at low levels on resting T cells and other normal tissue cells. This characteristic ensures high targeting specificity. This invention integrates the extracellular domain of human OX40L into a CAR structure, utilizing OX40 as a specific surface marker molecule for activated T cells. The CAR structure endows MSCs with antigen-specific recognition capabilities, enabling them to precisely locate and accumulate around overactivated T cells expressing OX40, thus achieving specific targeted regulation of pathologically activated T cells. Traditional mesenchymal cells lack targeting ability and are randomly distributed in vivo after infusion, making it difficult to efficiently accumulate at lesion sites. However, the mesenchymal cells of this invention, by specifically recognizing OX40 molecules on the surface of activated T cells, significantly increase the local concentration at aGVHD or CRS lesions, enhancing therapeutic efficiency.
[0042] This invention selectively inhibits pathogenic T cells with low side effects. In aGVHD, disease-mediating alloreactive T cells are highly activated and highly express OX40, while normal T cells that exert anti-infection and GVL effects are in a resting or partially activated state, with significantly lower OX40 expression levels. In CRS, overactivated CAR-T cells highly express OX40, while underactivated CAR-T cells and normal immune cells express lower levels of OX40. This invention selectively inhibits alloreactive T cells mediating aGVHD and overactivated CAR-T cells mediating CRS, while preserving resting or partially activated normal functional T cells, avoiding systemic immunosuppression and reducing the risk of opportunistic infections and tumor recurrence. Hormones are broad-spectrum immunosuppressants that inhibit the function of all T cells, increasing the risk of infection and recurrence, with a 2-year survival rate of only 17%. Compared to glucocorticoids, this invention selectively targets and activates T cells while preserving normal immune function. While IL-6 receptor antagonists can alleviate CRS symptoms, they also impair the anti-tumor activity of CAR-T cells. Compared to tocilizumab, this invention controls CRS while preserving the anti-tumor effect by regulating overactivated CAR-T cells rather than blocking their effector pathways.
[0043] This invention exhibits high safety and low immunogenicity. MSCs express low levels or no MHC class II molecules and co-stimulatory molecules (CD80, CD86), possessing immune-immune properties and can be used for allogeneic transplantation without inducing immune rejection. Unlike the cytotoxic killing mechanism of CAR-T, the mesenchymal cells of this invention exert their therapeutic effect through immune regulation rather than direct killing, avoiding cytokine release syndrome caused by the lysis of large numbers of target cells. Compared to CAR-T cell therapy, which is often accompanied by severe CRS and neurotoxicity, the mesenchymal cells of this invention, as immunomodulatory cells rather than effector cells, have significantly higher safety and can themselves be used to treat CAR-T-induced CRS.
[0044] This invention has a wide range of applications. Due to the biological characteristics of OX40 as a universal marker of T cell activation, pathogenic T cells upregulate OX40 expression in various T cell-mediated immunopathologies. Therefore, strategies targeting OX40 have broad application potential. This invention is not only applicable to aGVHD (including hormone-resistant aGVHD) and CAR-T therapy-related CRS, but can also be extended to other immune diseases related to T cell abnormalities or overactivation, such as chronic GVHD, autoimmune diseases, and organ transplant rejection. Attached Figure Description
[0045] Figure 1 The expression of OX40 in T cell subsets at different time points.
[0046] Figure 2 A schematic diagram of CAR-MSC construction.
[0047] Figure 3 The CAR positivity rate results for CAR-MSC.
[0048] Figure 4 The results of the identification of mesenchymal cell surface markers for CAR-MSC and UTD-MSC.
[0049] Figure 5 The results show the differentiation potential, aging, and proliferation capacity of CAR-MSCs and UTD-MSCs.
[0050] Figure 6 For OX40 + The effect of Jurkat pretreatment on the number of CAR-MSC suppressor T cells.
[0051] Figure 7 This is the result of the T cell proliferation test.
[0052] Figure 8 The results show the expression of T cell activation-related biomarkers.
[0053] Figure 9 The results show the proportions of Th1 and Th2 cells.
[0054] Figure 10 The results show the relative lysis rate of CAR-T cells against target cells.
[0055] Figure 11 The results show the expression of intracellular cytokines in CAR-T cells after target cell stimulation.
[0056] Figure 12 The results show the expression detection of the degranulation marker CD107a.
[0057] Figure 13 The results are bioluminescence imaging of a CAR-T tumor-bearing mouse model.
[0058] Figure 14 The results are from the survival analysis of the CAR-T tumor-bearing mouse model.
[0059] Figure 15 The results show the changes in body weight in CAR-T tumor-bearing mouse models.
[0060] Figure 16 Results of peripheral blood CAR-T cell count detection in CAR-T tumor-bearing mouse models.
[0061] Figure 17 The results of GVHD scoring in the humanized aGVHD mouse model.
[0062] Figure 18 Results of weight changes in the humanized aGVHD mouse model.
[0063] Figure 19 A representative mouse appearance photograph of the humanized aGVHD mouse model.
[0064] Figure 20 Survival analysis results of the humanized aGVHD mouse model.
[0065] Figure 21 HE staining, CD3 immunohistochemistry, and pathological scoring results of lung tissue from a humanized aGVHD mouse model.
[0066] Figure 22 Results of peripheral blood T cell count detection in humanized aGVHD mouse model.
[0067] Figure 23 Peripheral blood OX40 in humanized aGVHD mouse model + Results of T cell ratio assay.
[0068] Figure 24 This is a schematic diagram of a CAR-MSC variant structure containing different intra-sib signal domains.
[0069] Figure 25 This is the result of CAR expression detection in CAR-MSCs containing different intra-sib signal domains.
[0070] Figure 26 The results of weight, GVHD score, and survival analysis of different CAR-MSC variants in a humanized aGVHD model were presented.
[0071] Figure 27 HE staining and pathological scoring results of lung tissue in a humanized aGVHD model treated with different CAR-MSC variants.
[0072] Figure 28 HE staining and pathological scoring results of liver tissue in a humanized aGVHD model treated with different CAR-MSC variants.
[0073] Figure 29 Results of peripheral blood T cell count detection in a humanized aGVHD model treated with different CAR-MSC variants.
[0074] Figure 30 Different CAR-MSC variants were used to treat peripheral blood OX40 in a humanized aGVHD model. + Results of T cell ratio assay.
[0075] Figure 31 Results of MSC surface biomarker identification for different CAR-MSC variants.
[0076] Figure 32The results show the in vivo kinetic tracking of CAR-MSC and UTD-MSC in the aGVHD model.
[0077] Figure 33 For CAR-MSC and UTD-MSC in OX40 + In vivo dynamic tracking results from the Jurkat model.
[0078] Figure 34 The results show the ex vivo organ distribution of CAR-MSC and UTD-MSC in the aGVHD model. Detailed Implementation
[0079] This invention provides a chimeric antigen receptor that targets and activates T cells, comprising, from the N-terminus to the C-terminus, a signal peptide, an antigen recognition domain, a hinge region, a transmembrane domain, and an intracellular signal transduction domain; the amino acid sequence of the antigen recognition domain is shown in SEQ ID NO:2.
[0080] In this invention, the coding sequence of the antigen recognition domain is preferably as shown in SEQ ID NO:1. This invention selects the human OX40L extracellular domain as the antigen recognition domain, which can specifically recognize and bind to OX40 molecules on the surface of overactivated T cells, achieving specific targeted regulation of pathologically activated T cells.
[0081] Traditional chimeric antigen receptor structures typically employ single-chain antibodies (scFv) as the antigen recognition domain. scFv consists of a heavy chain variable region (VH) and a light chain variable region (VL) linked by a flexible linker peptide, and is an artificial fusion protein; its sequence itself is an exogenous structure for the human body. When used in cell therapy products derived from non-T cells, such as mesenchymal cells, long-term in vivo application carries the risk of inducing an anti-scFv immune response, potentially leading to the recognition and elimination of therapeutic cells by the host immune system, shortening the therapeutic window, and reducing the effectiveness of multiple doses. Furthermore, scFv exhibits folding instability and a tendency to form aggregates in certain cell types, affecting the correct display of CAR proteins on the cell membrane. This invention selects the extracellular receptor-binding domain of the human OX40 ligand (OX40L, TNFSF4) as the antigen recognition module. OX40L is a naturally occurring protein encoded by the human genome. Its extracellular receptor-binding domain amino acid sequence is entirely derived from human sequences, making it an intrinsic protein structure. It does not carry exogenous immunogenic determinants and exhibits good tolerability within the host immune system, significantly reducing the risk of therapeutic cell clearance due to immunogenicity of the recognition domain. This characteristic is particularly important for cell therapy regimens requiring multiple infusions. The binding between OX40L and its receptor OX40 exhibits naturally high affinity and specificity, with a Kd value at the nanomolar level. In contrast, anti-OX40 scFvs obtained through in vitro screening require additional affinity maturation and stability optimization, and scFvs from different screening sources show significant differences in affinity, making it difficult to guarantee quality consistency. Furthermore, OX40L interacts naturally with the trimer receptor-binding interface of OX40 through its receptor-binding domain, enabling precise recognition of functional epitopes on the natural conformation of OX40, avoiding the functional weakening problem caused by scFvs recognizing linear or non-functional conformational epitopes.
[0082] The mature human OX40L protein is 183 amino acids in length. The complete OX40L protein includes an intracellular domain (amino acids 1-23), a transmembrane domain (amino acids 24-51), and an extracellular receptor-binding domain (amino acids 52-183). OX40L is a type II transmembrane protein. If the N-terminal intracellular and transmembrane domains are retained and fused into the CAR backbone, additional hydrophobic transmembrane sequences will be introduced, interfering with the correct topological orientation and functional folding of the CAR protein on the cell membrane. Amino acid 52 (Val) is the natural start site of the extracellular receptor-binding domain. Using this as a cutoff point precisely preserves the complete receptor-binding functional module while avoiding the introduction of non-receptor-binding sequences. Furthermore, the OX40L amino acid sequence from 52 to 183 is only 132 amino acids long, significantly smaller than typical scFv. The reduced molecular weight of the recognition domain helps reduce the steric hindrance of the entire CAR protein, thereby enabling more efficient contact with OX40 molecules on the target cell surface and improving the effective binding rate. Furthermore, the extracellular domain of OX40L forms a typical TNF homologous domain (THD), consisting of antiparallel β-sheets forming a β-jellyroll three-dimensional conformation. Three OX40L monomers must form a homotrimer before they can bind to the OX40 receptor with high affinity. The amino acid sequence from positions 52 to 183 completely contains the entire β-chain and key loop region of the THD, preserving the complete structural information required for the formation of a functional trimer conformation, thus maintaining the high-affinity trimer binding mode with OX40. If the truncation is too short (e.g., retaining only a portion of the β-chain), the integrity of the THD will be compromised, weakening the trimer formation ability and receptor binding affinity. Therefore, this invention selects amino acid sequences from position 52 to 183 as the CAR recognition domain, precisely extracts the functional receptor binding domain, and removes transmembrane and intracellular structures, resulting in a small CAR recognition domain sequence and small molecular weight, which is beneficial for the membrane surface display of CAR protein. The CAR positivity rate of CAR-MSCs in this invention can reach over 95%, which reflects the high-efficiency expression characteristics of this construct in MSCs. The β-jellyroll fold structure domain of the TNF superfamily ligand is completely preserved, maintaining the high-affinity trimer binding mode with OX40.
[0083] In this invention, the signal peptide guides the chimeric antigen receptor (CAR) protein to the correct localization to the cell membrane surface. The signal peptide preferably includes the CD8α signal peptide; in some embodiments, the coding sequence of the CD8α signal peptide is shown in SEQ ID NO:3, and the amino acid sequence is shown in SEQ ID NO:4.
[0084] In this invention, the hinge region provides flexibility to the CAR structure, allowing the antigen recognition domain to spatially approach the target cell surface antigen while influencing the orientation of the CAR molecule on the cell membrane. The hinge region preferably includes a CD8α hinge region, a CD28 hinge region, an IgG1 Fc hinge region, or an IgG4 Fc hinge region. In some embodiments, the coding sequence of the CD8α hinge region is shown in SEQ ID NO:5, and the amino acid sequence is shown in SEQ ID NO:6. In other embodiments, the IgG4 Fc hinge region preferably includes a short IgG4 Fc hinge region, a medium IgG4 Fc hinge region, or a long IgG4 Fc hinge region; the coding sequence of the short IgG4 Fc hinge region is shown in SEQ ID NO:20, and the amino acid sequence is shown in SEQ ID NO:21; the coding sequence of the medium IgG4 Fc hinge region is shown in SEQ ID NO:22, and the amino acid sequence is shown in SEQ ID NO:23; the coding sequence of the long IgG4 Fc hinge region is shown in SEQ ID NO:24, and the amino acid sequence is shown in SEQ ID NO:25, for applications requiring longer spatial distances.
[0085] In this invention, the transmembrane domain (TM) can anchor the CAR protein to the cell membrane, maintaining its stability and correct localization. The transmembrane domain preferably includes a CD8α transmembrane domain, a CD28 transmembrane domain, a CD3ζ transmembrane domain, or a 4-1BB transmembrane domain; in some embodiments, the coding sequence of the CD8α transmembrane domain is shown in SEQ ID NO:7, and the amino acid sequence is shown in SEQ ID NO:8.
[0086] In this invention, the intracellular signal transduction domain preferably includes an activation domain and / or a co-stimulatory domain. The activation domain can transmit activation signals and trigger functional responses in MSCs, while the co-stimulatory domain can enhance CAR-mediated cell activation signals and regulate the immunomodulatory function of MSCs.
[0087] The activation domain preferably includes a CD3ζ activation domain; the CD3ζ activation domain contains three immune receptor tyrosine activation motifs (ITAMs); in some embodiments, the coding sequence of the CD3ζ activation domain is shown in SEQ ID NO:11, and the amino acid sequence is shown in SEQ ID NO:12.
[0088] The costimulatory domains preferably include one or more of the following: CD28 costimulatory domain, 4-1BB (CD137) costimulatory domain, OX40 (CD134) costimulatory domain, ICOS costimulatory domain, CD27 costimulatory domain, and CD40 costimulatory domain. The number of costimulatory domains is preferably 1 to 3, for example, 2.
[0089] In some embodiments, when the costimulation domain is a single costimulation domain, the costimulation domain is preferably any one of the following: CD28 costimulation domain, 4-1BB costimulation domain, OX40 costimulation domain, ICOS costimulation domain, CD27 costimulation domain, or CD40 costimulation domain.
[0090] In some embodiments, when the co-stimulatory region is a dual co-stimulatory region, the co-stimulatory region is preferably a combination of CD28+4-1BB, CD28+OX40, or 4-1BB+OX40. In the CD28+4-1BB dual co-stimulatory region, the CD28 co-stimulatory region is at the N-terminus, and the 4-1BB co-stimulatory region is at the C-terminus.
[0091] In some embodiments, when the costimulatory domain is a triple costimulatory domain, the costimulatory domain is preferably a combination of CD28+4-1BB+OX40, etc.
[0092] In some specific embodiments, the coding sequence of the 4-1BB co-stimulatory domain is shown in SEQ ID NO:9, and the amino acid sequence is shown in SEQ ID NO:10. The coding sequence of the CD28 co-stimulatory domain is shown in SEQ ID NO:26, and the amino acid sequence is shown in SEQ ID NO:27.
[0093] In this invention, the intracellular signal transduction domain may contain only an activation domain, only a co-stimulatory domain, or both an activation domain and a co-stimulatory domain. Experimental results of this invention confirm that containing only a co-stimulatory domain or both an activation domain and a co-stimulatory domain results in stronger targeted immunosuppressive function. Furthermore, chimeric antigen receptors containing both activation and co-stimulatory domains exhibit optimal performance, indicating that the synergistic combination of activation and co-stimulatory domains is a key design choice for achieving optimal immunomodulatory efficacy.
[0094] In this invention, the chimeric antigen receptor preferably includes first to fourth generation, and is preferably a second-generation chimeric antigen receptor (containing one co-stimulatory domain) or a third-generation chimeric antigen receptor (containing two co-stimulatory domains). In some specific embodiments, when the chimeric antigen receptor is a second-generation chimeric antigen receptor, the complete chimeric antigen receptor structure is: N-terminus - signal peptide - OX40L extracellular binding domain - CD8α hinge region - CD8α transmembrane domain - 4-1BB co-stimulatory domain - CD3ζ activation domain - C-terminus. In other specific embodiments, when the chimeric antigen receptor is a third-generation chimeric antigen receptor, the complete chimeric antigen receptor structure is: N-terminus - signal peptide - OX40L extracellular binding domain - CD8α hinge region - CD8α transmembrane domain - CD28 co-stimulatory domain - 4-1BB co-stimulatory domain - CD3ζ activation domain - C-terminus.
[0095] In some specific embodiments of the present invention, the amino acid sequence of the chimeric antigen receptor is shown in SEQ ID NO:14.
[0096] The present invention also provides a nucleic acid molecule encoding the chimeric antigen receptor. In some specific embodiments, the nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO:13.
[0097] The present invention also provides a recombinant expression vector comprising the nucleic acid molecule.
[0098] In this invention, the type of recombinant expression vector is not particularly limited, but preferably includes lentiviral vectors, retroviral vectors, adeno-associated virus vectors, transposon systems, or non-viral vectors; the transposon system preferably includes piggyBac or Sleeping Beauty; the non-viral vector preferably includes plasmids or mRNA electroporation; in some embodiments, the recombinant expression vector is preferably a third-generation self-inactivating (SIN) lentiviral vector system.
[0099] In this invention, the length of the nucleic acid molecule is preferably 1.0~2.5kb, more preferably 1.1~1.8kb, and even more preferably 1.12~1.65kb.
[0100] In this invention, the recombinant expression vector preferably further comprises a promoter capable of driving the expression of the CAR gene. The promoter preferably includes a constitutive promoter or an inducible promoter; the constitutive promoter preferably includes EF-1α, CMV, PGK, CAG, UBC, or SFFV; the inducible promoter preferably includes a Tet-on / Tet-off system or a rapamycin induction system. In some embodiments, the promoter preferably includes an EF-1α promoter or a PGK promoter, more preferably an EF-1α promoter; the coding sequence of the EF-1α promoter is preferably as shown in SEQ ID NO:15, approximately 1.2 kb in length, and exhibits high and stable expression intensity in MSCs.
[0101] In this invention, the recombinant expression vector preferably further comprises a termination signal sequence. The termination signal sequence preferably includes SV40 polyA, BGH polyA, or HSV TK polyA.
[0102] In this invention, the recombinant expression vector preferably further comprises a post-transcriptional regulatory element, which preferably includes a sloth hepatitis virus post-transcriptional regulatory element (WPRE). In some specific embodiments, the recombinant expression vector preferably comprises a WPRE+BGH polyA combination.
[0103] In this invention, the recombinant expression vector preferably further comprises a selection marker for screening positive transduced cells. The selection marker preferably includes an antibiotic resistance gene, a fluorescent protein, or a truncated surface marker. The antibiotic resistance gene preferably includes a puromycin resistance gene (PuroR), a neomycin resistance gene (NeoR), or a hygromycin resistance gene (HygroR); in some embodiments, the puromycin resistance gene preferably includes the pac gene; the coding sequence of the pac gene is shown in SEQ ID NO:16, and the amino acid sequence is shown in SEQ ID NO:17. The fluorescent protein is preferably GFP, mCherry, or tdTomato. The truncated surface marker preferably includes truncated CD19 (tCD19), truncated EGFR (tEGFR), or truncated NGFR (tNGFR).
[0104] The selectable marker is linked to the nucleic acid molecule, preferably via a 2A autorepeptide or an IRES sequence; the 2A autorepeptide preferably includes T2A, P2A, E2A, or F2A. In some embodiments, the coding sequence of T2A is shown in SEQ ID NO:18, and the amino acid sequence is shown in SEQ ID NO:19. In other embodiments, the coding sequence of P2A is shown in SEQ ID NO:28, and the amino acid sequence is shown in SEQ ID NO:29. Linking the nucleic acid molecule via P2A forms a CAR-P2A-tEGFR structure, which facilitates flow cytometry detection of positive rates without affecting CAR function. In other embodiments, the coding sequence of E2A is shown in SEQ ID NO:30, and the amino acid sequence is shown in SEQ ID NO:31; the coding sequence of F2A is shown in SEQ ID NO:32, and the amino acid sequence is shown in SEQ ID NO:33.
[0105] In this invention, the recombinant expression vector preferably further comprises other regulatory elements; the other regulatory elements preferably include one or more of 5'LTR (long terminal repeat), 3'SIN-LTR (self-inactivating long terminal repeat, U3 region deletion), Ψ packaging signal, RRE (Rev response element), and cPPT / CTS (central polypurine bundle / central termination sequence).
[0106] This invention also provides a mesenchymal cell comprising the aforementioned nucleic acid molecule or the aforementioned recombinant expression vector. The mesenchymal cells (MSCs) of this invention, by expressing the aforementioned chimeric antigen receptor and utilizing the CAR structure to endow MSCs with antigen-specific recognition capabilities, can precisely locate and accumulate around overactivated T cells expressing OX40. Furthermore, by utilizing the immunomodulatory capabilities of mesenchymal cells, they inhibit excessive T cell proliferation and the release of inflammatory cytokines, thereby achieving specific targeted regulation of pathologically activated T cells. Traditional MSCs lack targeting and are randomly distributed in vivo after infusion, making it difficult to efficiently accumulate at lesion sites; however, the mesenchymal cells of this invention, by specifically recognizing OX40 molecules on the surface of activated T cells, significantly increase the local concentration at the lesion site, enhancing therapeutic efficiency.
[0107] In this invention, the source of the mesenchymal cells is not specifically limited, but preferably includes bone marrow-derived mesenchymal cells (BM-MSC), adipose tissue-derived mesenchymal cells (AD-MSC), umbilical cord-derived mesenchymal cells (UC-MSC), umbilical cord blood-derived mesenchymal cells (UCB-MSC), placental-derived mesenchymal cells (PL-MSC), dental pulp-derived mesenchymal cells (DP-MSC), amnion-derived mesenchymal cells (AM-MSC), or synovial membrane-derived mesenchymal cells (SM-MSC); more preferably, umbilical cord-derived mesenchymal cells or bone marrow-derived mesenchymal cells, because they have strong immunomodulatory capabilities, good proliferative capacity, and are relatively easy to obtain clinically.
[0108] The mesenchymal cells are preferably from the 3rd to 5th generation, such as the 4th generation. In some specific embodiments, the 1st generation mesenchymal cells are used for infection, and the 2nd generation are cryopreserved for seed preservation. After thawing, the 3rd to 5th generation cells are obtained for subsequent applications.
[0109] The phenotypic characteristics of the mesenchymal cells meet the MSC criteria defined by the International Society for Cell Therapy (ISCT).
[0110] In terms of morphological characteristics, the mesenchymal cells appear as spindle-shaped or fusiform fibroblast-like morphologies under a microscope, grow adherently to the wall, and are arranged in a whorl or parallel pattern.
[0111] Regarding the expression profile of surface markers, flow cytometry analysis showed that the mesenchymal cells were positive for CD73, CD90, and CD105; the CD73 positivity rate was preferably ≥95%, more preferably ≥98%; the CD90 positivity rate was preferably ≥95%, more preferably ≥98%; and the CD105 positivity rate was preferably ≥95%, more preferably ≥98%. The mesenchymal cells were also negative for CD34, CD45, CD14 or CD11b, CD19 or CD79α, and HLA-DR; the CD34 positivity rate was preferably ≤2%, more preferably ≤1%; the CD45 positivity rate was preferably ≤2%, more preferably ≤1%; the CD14 or CD11b positivity rate was preferably ≤2%, more preferably ≤1%; the CD19 or CD79α positivity rate was preferably ≤2%, more preferably ≤1%; and the HLA-DR positivity rate was preferably ≤2%, more preferably ≤1%.
[0112] The mesenchymal cells express the chimeric antigen receptor described in this invention. The CAR positivity rate can be detected by flow cytometry, and CAR-positive cells can be enriched by puromycin screening.
[0113] Regarding cell viability, the cell viability was preferably ≥85%, further preferably ≥90%, and even more preferably ≥95%, as determined by trypan blue staining exclusion method.
[0114] Regarding differentiation potential, the mesenchymal cells possess the potential for outward differentiation into osteoblasts, adipocytes, and chondrocytes. In some embodiments, after osteogenic induction for 14–21 days, Alizarin Red staining or alkaline phosphatase activity assay shows a positive staining area ≥30% of the field of view; after adipogenic induction for 14–21 days, Oil Red O staining shows positive staining cells ≥30%; and after chondrogenic induction for 21–28 days, Alixin Blue staining or type II collagen immunohistochemistry shows significant positive staining.
[0115] The present invention also provides a method for preparing the mesenchymal cells, comprising: introducing the nucleic acid molecule or the recombinant expression vector into primitive mesenchymal cells to obtain the mesenchymal cells.
[0116] In this invention, the original mesenchymal cells are preferably first-generation mesenchymal cells. The original mesenchymal cells are cultured and expanded in vitro before introduction. The culture conditions for the original mesenchymal cells are as follows: the basal medium is α-MEM, supplemented with fetal bovine serum (FBS), the concentration of which is preferably 5%~20% (v / v), more preferably 10%~15%, and even more preferably 10%; penicillin-streptomycin antibiotics (p / s) may also be added to the basal medium, the concentration of which is preferably 0.5%~1.5%, and even more preferably 1%; the culture temperature is preferably 37±0.5℃, the CO2 concentration is preferably 5%±0.5%, and the humidity is preferably ≥95%. Under the above conditions, when the cell confluence reaches 40%~70%, preferably 50%~60%, the cells are introduced.
[0117] In this invention, the preferred method of introduction is viral infection, with an infection multiplicity preferably of 1-100, more preferably 10. The viral infection preferably includes co-culturing a recombinant virus containing the nucleic acid molecule with primitive mesenchymal cells for a co-culturing time preferably 60-80 hours, more preferably 64-76 hours, and more preferably 66-72 hours. For resistance screening, puromycin at a final concentration of 2-10 μg / mL, preferably 5 μg / mL, can be added starting 60-80 hours after infection, preferably 72 hours, and screening can continue for approximately 3-7 days until a sufficient number of cells are obtained.
[0118] The screened CAR-MSCs were further expanded and cultured, and then cryopreserved. At harvest, the cells were digested with 0.05%–0.25% Trypsin-EDTA or animal-free TrypLE Express, preferably 0.05% Trypsin-EDTA, for a digestion time of 3 minutes at a temperature of 37°C. After digestion, the cells were resuspended to prepare a cell suspension, preferably with a concentration of 1 × 10⁻⁶. 6 ~5×10 7 Cells / mL, more preferably 5 × 10⁻⁶ 6 ~2×10 7 Cells / mL, more preferably 5 × 10⁶ / mL 6 Cells / mL. For cryopreservation, the cryopreservation solution preferably contains a base solution and a cryoprotectant. The base solution preferably includes 90% FBS or a clinical-grade serum substitute, and the cryoprotectant preferably includes 10% DMSO; alternatively, a DMSO-free clinical-grade cryopreservation solution, such as one containing sucrose or trehalose, can be used. The freezing process should be controlled at a cooling rate of -1°C / min. After cooling to -80°C, the solution should be transferred to liquid nitrogen for storage. The freezing temperature should be ≤-150°C, using liquid nitrogen gas or liquid phase.
[0119] In some specific embodiments, the method for preparing the mesenchymal cells includes: co-transfecting a recombinant lentiviral vector containing the nucleic acid molecule and a packaging plasmid into 293T cells, culturing them, collecting the supernatant, and obtaining lentivirus; infecting the mesenchymal cells in the first generation with the lentivirus; after infection, screening for positive cells to obtain mesenchymal cells that stably express the chimeric antigen receptor.
[0120] The packaging plasmid preferably comprises psPAX2 and pMD2.G; the mass ratio of the recombinant lentiviral vector, psPAX2, and pMD2.G is preferably (30~35):(15~20):(5~10), more preferably 34:17:8.5. The culture conditions preferably include culture at 37°C and 5% CO2. The supernatant is preferably collected 24~48 h after transfection, and the supernatant is preferably centrifuged and filtered to obtain lentivirus; the centrifugation conditions preferably include centrifugation at 2000g, 4°C for 10 min; the filtration aperture is preferably 0.45 μm.
[0121] The lentivirus is used to infect first-generation mesenchymal cells, preferably first-generation mesenchymal cells in the logarithmic growth phase with a cell confluence of 50% to 60%, and the lentivirus is added and incubated at 37°C and 5% CO2. The multiplicity of infection of the lentivirus is preferably 1 to 100, more preferably 10.
[0122] Sixty to 80 hours post-infection, preferably 72 hours, positive cell screening is performed to obtain mesenchymal cells stably expressing the chimeric antigen receptor. In some specific embodiments, the recombinant lentiviral vector contains a puromycin resistance gene. After infection, the culture medium is replaced with a complete medium containing puromycin for positive cell screening. The final concentration of puromycin is preferably 2 to 10 μg / mL, more preferably 5 μg / mL. Screening continues to remove cells that have not been successfully transduced.
[0123] After obtaining mesenchymal cells that stably express the chimeric antigen receptor, it is preferable to cryopreserve them at the second generation, and then use the mesenchymal cells from the third to fifth generations after thawing for subsequent applications.
[0124] The present invention also provides the use of the mesenchymal cells described above in the preparation of products for the treatment and / or prevention of diseases related to abnormal or excessive activation of T cells.
[0125] In this invention, the T-cell abnormality or overactivation-related diseases preferably include graft-versus-host disease (GVHD), side effects caused by CAR-T therapy, autoimmune diseases, or organ transplant rejection. The GVHD preferably includes acute GVHD or chronic GVHD; the acute GVHD preferably includes hormone-resistant acute GVHD. The side effects caused by CAR-T therapy preferably include cytokine release syndrome.
[0126] The mesenchymal cells of this invention can reduce the proliferation of activated T cells and the expression of early activation markers CD69, activated T cell-specific markers OX40, and IL-2 receptor α chain CD25. The inhibitory effect on CD69 is significantly stronger than that of primitive mesenchymal cells, effectively inhibiting the activated state of activated T cells and suppressing T cell activation. The mesenchymal cells of this invention can significantly reduce the proportion of Th1 cells and increase the proportion of Th2 cells, with a stronger effect than that of primitive mesenchymal cells. They can inhibit Th1 cell differentiation and promote Th2 cell differentiation, thereby downregulating the Th1 / Th2 ratio and reshaping T cells to shift towards immune tolerance.
[0127] The mesenchymal cells of this invention can significantly inhibit the activation and effector function of CAR-T cells, mainly by reducing the effect of CAR-T cells on CD19 at the in vitro level. + The invention enhances the tumor-killing activity of CAR-T cells and inhibits the excessive secretion of pro-inflammatory factors such as IFN-γ and IL-2. It also weakens the tumor control ability of CAR-T cells at in vivo levels and inhibits their in vivo expansion. The invention exerts the above-mentioned regulatory effects without causing significant systemic toxicity. The regulatory efficacy of the mesenchymal cells in this invention is significantly better than that of the original mesenchymal cells, indicating that the introduction of the CAR structure in this invention can enhance the targeted inhibition ability of mesenchymal cells against the overactivation of CAR-T cells.
[0128] The mesenchymal cells of this invention can reduce the number of peripheral blood T cells in a humanized aGVHD model, especially reducing OX40. + CD4 + The increased T-cell ratio improved clinical symptoms and body weight in aGVHD, reduced inflammatory damage to target organs in aGVHD, and prolonged the survival of model animals. The regulatory efficacy of mesenchymal cells in this invention was significantly superior to that of primitive mesenchymal cells, indicating that the introduction of the CAR structure in this invention endows mesenchymal cells with the ability to target and inhibit activated T cells, thereby enhancing its therapeutic efficacy in aGVHD.
[0129] The mesenchymal cells of this invention exhibit a characteristic biological distribution pattern of enrichment in lesions in vivo. In the aGVHD model, they are cleared faster than the original mesenchymal cells. This accelerated clearance reflects the result of the mesenchymal cells of this invention actively participating in the immune response in inflammatory lesions, rather than the stability defects caused by the CAR structure. This supports the core mechanism of the CAR engineering strategy of this invention, which enables mesenchymal cells to target and locate at sites of activated T cell aggregation, thereby maximizing their local immune regulation efficacy.
[0130] The present invention also provides a pharmaceutical composition comprising the mesenchymal cells and a pharmaceutically acceptable carrier.
[0131] In this invention, the mesenchymal cells in the pharmaceutical composition can be used alone as the sole active ingredient, or, as needed, can be further included with one or more other active ingredients to achieve combined therapy or synergistic effects. The types of the other active ingredients are not particularly limited, but preferably include, but are not limited to, immunosuppressants, anti-inflammatory drugs, or cytokine antagonists.
[0132] In this invention, there is no particular limitation on the pharmaceutically acceptable type of carrier; any carrier capable of maintaining the activity and function of the mesenchymal cells can be used. The pharmaceutical composition may also further include, as needed, excipients conventional in the art, such as stabilizers, isotonic modifiers, buffers, or preservatives, to enhance the stability and safety of the formulation.
[0133] In this invention, the dosage form of the pharmaceutical composition is not particularly limited and can be formulated into an appropriate dosage form according to the route of administration, including injections, lyophilized powder injections, or cell suspensions. Those skilled in the art can select appropriate carriers and excipients according to actual needs to prepare pharmaceutical compositions that meet clinical requirements.
[0134] The pharmaceutical composition of the present invention can be administered by intravenous infusion, local injection, intraperitoneal injection or other methods suitable for cell therapy.
[0135] The pharmaceutical composition of the present invention is preferably administered by intravenous infusion.
[0136] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.
[0137] Unless otherwise specified, the following embodiments are all conventional methods.
[0138] Unless otherwise specified, all materials and reagents used in the following examples are commercially available.
[0139] Example 1 A chimeric antigen receptor that targets and activates T cells, comprising, from N-terminus to C-terminus: signal peptide, antigen recognition domain, hinge region, transmembrane domain, and intracellular signal transduction domain; The signal peptide is a CD8α signal peptide, and its amino acid sequence is shown in SEQ ID NO:4; The amino acid sequence of the antigen recognition domain is shown in SEQ ID NO:2; The hinge region is the CD8α hinge region, and the amino acid sequence is shown in SEQ ID NO:6; The transmembrane domain is the CD8α transmembrane domain, and its amino acid sequence is shown in SEQ ID NO:8; The intracellular signal transduction domain is the CD3ζ activation domain, and its amino acid sequence is shown in SEQ ID NO:12.
[0140] Example 2 A chimeric antigen receptor that targets and activates T cells, the only difference from Example 1 is that the intracellular signal transduction domain is a 4-1BB co-stimulatory domain, and the amino acid sequence is shown in SEQ ID NO:10.
[0141] Example 3 A chimeric antigen receptor targeting activated T cells, the only difference from Example 1 is that the intracellular signal transduction domain is composed of a co-stimulatory domain and an activation domain, the co-stimulatory domain is a 4-1BB co-stimulatory domain, the amino acid sequence of which is shown in SEQ ID NO:10; the activation domain is a CD3ζ activation domain, the amino acid sequence of which is shown in SEQ ID NO:12.
[0142] Example 4 A chimeric antigen receptor that targets and activates T cells, the only difference from Example 3 is that the co-stimulatory domain is a CD28 co-stimulatory domain and a 4-1BB co-stimulatory domain.
[0143] Example 5 A chimeric antigen receptor that targets and activates T cells, the only difference from Example 3 is that the co-stimulatory domains are ICOS co-stimulatory domain, CD27 co-stimulatory domain and CD40 co-stimulatory domain.
[0144] Example 6 A chimeric antigen receptor that targets and activates T cells, the only difference from Example 3 is that the hinge region is the CD28 hinge region; and the transmembrane domain is the CD28 transmembrane domain.
[0145] Example 7 A chimeric antigen receptor that targets and activates T cells, the only difference from Example 3 is that the hinge region is the IgG1 Fc hinge region; and the transmembrane domain is the CD3ζ transmembrane domain.
[0146] Example 8 A chimeric antigen receptor that targets and activates T cells, differing from Example 3 only in that the hinge region is a long IgG4 Fc hinge region, with the amino acid sequence shown in SEQ ID NO:25; and the transmembrane domain is a 4-1BB transmembrane domain.
[0147] Example 9 A mesenchymal cell comprising a nucleic acid molecule expressing the chimeric antigen receptor of Example 3; said mesenchymal cell is an umbilical cord-derived mesenchymal cell; The method for preparing the mesenchymal cells is as follows: co-culturing recombinant viruses containing the nucleic acid molecules with umbilical cord-derived mesenchymal cells; screening the infected cells for positive cells to obtain mesenchymal cells that stably express chimeric antigen receptors.
[0148] Example 10 A mesenchymal cell comprising a nucleic acid molecule expressing the chimeric antigen receptor of Example 4; said mesenchymal cell is a bone marrow-derived mesenchymal cell.
[0149] Example 11 A mesenchymal cell comprising a nucleic acid molecule expressing the chimeric antigen receptor of Example 5; said mesenchymal cell is an adipose tissue-derived mesenchymal cell.
[0150] Experimental Example 1 1. Expression of OX40 during T cell activation T cells were activated using DynaBeads CD3 / CD28 CTSTM (Gibco, catalog number 40203D) under culture conditions of 37℃ and 5% CO2. Flow cytometry was used to detect the expression of OX40 in T cell subsets at different time points. Results are as follows: Figure 1 As shown, with the activation of T cells, the abundance of OX40 in T cells first increased, reached a peak on the second day, then gradually decreased, and dropped below the baseline on the fifth day. The CD4 positive T cell subset was significantly higher than the CD8 positive T cell subset.
[0151] 2. Construct a chimeric antigen receptor expression vector targeting OX40 Based on bioinformatics analysis, and considering the amino acid sequence (NP_003317.1) of the human OX40 ligand (OX40L / CD252 / TNFSF4) and its molecular characteristics of specific binding to the receptor OX40 (CD134 / TNFRSF4), the extracellular domain of human OX40L (encoding amino acids 52-183) was selected as the OX40 recognition domain (SEQ ID NO:2). The CD8α signal peptide sequence was further added, and the OX40L extracellular domain sequence was sequentially tandemly arranged with the CD8α hinge region sequence, CD8α transmembrane region sequence, 4-1BB co-stimulatory region sequence, and CD3ζ activation region sequence, as shown in Table 1. The coding sequence of the chimeric antigen receptor targeting OX40 was constructed as shown in SEQ ID NO:13, and the amino acid sequence is shown in SEQ ID NO:14. A schematic diagram of CAR-MSC construction is shown below. Figure 2 As shown.
[0152] Using molecular cloning technology, the above-mentioned chimeric antigen receptor coding sequence targeting OX40 was cloned into a lentiviral vector and placed under the regulation of the EF-1α promoter. At the same time, the puromycin resistance gene (pac gene) was added and linked to the chimeric antigen receptor targeting OX40 through the T2A linker peptide for puromycin screening to improve the CAR positivity rate. The specific sequence is shown in Table 1.
[0153] Table 1 Related Sequences
[0154] 3. Preparation and identification of chimeric antigen receptor mesenchymal cells targeting OX40. 3.1 Preparation of Lentiviral Viruses Lentiviral vectors were used to produce lentiviruses in 293T cell lines. Specifically, 34 μg of the lentiviral vector plasmid, 17 μg of psPAX2, and 8.5 μg of pMD2.G packaging plasmid were co-transfected into 293T cells that had grown to 80% confluence in T175 culture flasks using X-treme GENE HP DNA transfection reagent (Roche, catalog number 06366236001). Cells were cultured at 37°C and 5% CO2. Viral supernatant was collected 48 h post-transfection. The supernatant sample was centrifuged at 2000g × 4°C for 10 min to remove cell debris, filtered through a 0.45 μm filter membrane, and stored at 4°C for later use.
[0155] To determine the viral titer of the obtained viral fluid, 50 μL of viral fluid was used to infect 293T cells. The CAR expression positivity rate of 293T cells was detected by flow cytometry, and the viral titer was calculated. The results showed that the titer of 50 μL of viral fluid was 2.1 × 10⁻⁶. 7 TU.
[0156] 3.2 Preparation and identification of chimeric antigen receptor mesenchymal cells targeting OX40 The lentivirus obtained from the above packaging was used to infect human umbilical cord mesenchymal cells (hUC-MSCs) in passage 1 (P1 generation). Specifically, P1 generation hUC-MSCs in logarithmic growth phase with a cell confluence of 50%-60% were taken, and the above lentivirus was added at a multiplicity of infection of 10. The cells were then incubated at 37°C and 5% CO2 for 72 hours.
[0157] 72 hours post-infection, the medium was replaced with complete culture medium containing puromycin (α-MEM + 10% FBS + 1% penicillin-streptomycin (p / s)) for positive cell selection. The final concentration of puromycin was 5 μg / mL. Selection continued to remove unsuccessfully transduced cells to obtain mesenchymal cells (CAR-MSCs) stably expressing the chimeric antigen receptor. The selected cells were expanded and cultured, and cryopreserved at passage 2 (P2). After thawing, CAR-MSCs from passages 3 to 5 (P3-P5) were used for subsequent in vitro and in vivo functional experiments.
[0158] The CAR positivity rate of the obtained CAR-MSCs was detected by flow cytometry as follows: Figure 3 As shown, the CAR positivity rate can reach over 95%. The CAR-MSCs were subjected to mesenchymal cell surface marker and stemness identification, and the results are as follows: Figure 4 As shown, CAR-MSCs highly expressed mesenchymal cell-specific positive markers (CD73, CD90, CD105, with positive rates ≥95%) and expressed low or no hematopoietic and endothelial cell-related negative markers (CD34, CD45, CD14, with positive rates ≤2%), meeting the mesenchymal cell identification criteria stipulated by the International Society for Cell Therapy (ISCT). Furthermore, the expression levels of these markers showed no statistical difference compared to untransduced mesenchymal cells (UTD-MSCs). In addition, CAR-MSCs retained osteogenic and adipogenic differentiation potential after in vitro induction. Adipogenic differentiation was confirmed by Oil Red O staining, and osteogenic differentiation was confirmed by alkaline phosphatase (ALP) staining and Alizarin Red S staining, both of which showed no statistical difference compared to UTD-MSCs. Figure 5 Meanwhile, EdU incorporation assays and SA-β-galactosidase staining results showed no significant difference between CAR-MSCs and UTD-MSCs in terms of proliferation capacity and cellular senescence. Figure 5 The above results indicate that the lentiviral transduction and puromycin screening process did not affect the inherent phenotypic characteristics, multi-lineage differentiation potential, and proliferation properties of mesenchymal cells, and the prepared CAR-MSCs retained the key biological characteristics of the parental MSCs.
[0159] 4. In vitro immunomodulatory effects of CAR-MSCs on activated T cells This experiment established an in vitro co-culture system including a Jurkat pretreatment step. Specifically, UTD-MSCs or CAR-MSCs were seeded in 12-well plates at a MSC:PBMC ratio of 1:10. In the experimental group with Jurkat pretreatment, MSCs were first mixed with control Jurkat cells (OX40 negative) or OX40 negative cells. + After co-culturing Jurkat cells at a 1:10 ratio for 24 h, the Jurkat cells were gently washed away, and PBMCs were activated by adding 5 μM CFSE-labeled CD3 / CD28 magnetic beads. In the untreated group, MSCs were directly co-cultured with activated PBMCs. All co-cultures were maintained for 48 h in RPMI-1640 medium containing 20% fetal bovine serum and 30 IU / mL IL-2. After co-culture, suspension cells were collected for flow cytometry analysis. In addition, in the co-culture group without Jurkat pretreatment, T cell activation markers and Th1 / Th2 polarization were further detected.
[0160] 4.1 OX40-specific contact enhances the inhibitory activity of CAR-MSCs against T cells. To clarify whether specific contact between CAR and target antigen can enhance the inhibitory function of CAR-MSCs, this experiment used OX40 + Jurkat cells were pretreated with MSCs to detect their inhibitory effect on activated PBMCs.
[0161] It is worth noting that although CD3 / CD28 magnetic bead-activated PBMCs themselves also upregulate OX40 expression, the Jurkat pretreatment experimental design can isolate the contribution of CAR-OX40 specific contact from the overall signal in subsequent co-culture, thereby independently verifying the effect of CAR structure on MSC function.
[0162] The results are as follows Figure 6 As shown, OX40 + Jurkat pretreatment significantly reduced the absolute number of T cells in subsequent co-culture of CAR-MSCs, showing statistically significant differences compared to both the untreated group (p=0.0011) and the control Jurkat pretreated group (p=0.0052); while the number of T cells in the UTD-MSC group did not differ significantly under the three pretreatment conditions. These results indicate that the specific contact between CAR and OX40 can confer additional inhibitory gains on CAR-MSCs, and this gain is antigen-specific.
[0163] 4.2 CAR-MSCs inhibit T cell proliferation T cell proliferation was detected using the CFSE labeling method. The results showed that ( Figure 7In the direct co-culture system without Jurkat pretreatment, the percentage of T cell division (% Divided cells) in the CAR-MSC group was significantly lower than that in the UTD-MSC group and the T cell only group, indicating that CAR-MSC has a stronger inhibitory effect on T cell proliferation than untransduced mesenchymal cells.
[0164] 4.3 CAR-MSCs selectively inhibit the expression of T cell activation markers Further detection of the expression of T cell activation-related markers ( Figure 8 The results showed that, compared with the T cell only group, the CD3 levels in the CAR-MSC group and the UTD-MSC group were significantly higher. + The positive rates of CD69 and CD25, early activation markers on the T cell surface, were significantly reduced, with the inhibitory effect of the CAR-MSC group being significantly stronger than that of the UTD-MSC group. The proportion of OX40-positive T cells was significantly lower in both MSC treatment groups than in the T cell-only group, with no statistically significant difference between UTD-MSC and CAR-MSC (p=0.8917). There was no significant difference in the expression of the unrelated activation marker CD30 among the groups, ruling out the possibility of broad-spectrum non-specific inhibition. These results indicate that CAR-MSC can effectively and selectively inhibit the expression of key activation markers of activated T cells.
[0165] 4.4 CAR-MSC Regulation of CD4 + T cell Th1 / Th2 differentiation balance To further evaluate CAR-MSC's effect on CD4 + The influence of helper T cell differentiation direction was investigated in this experiment using intracellular cytokine staining to detect Th1 (IFN-γ) cells. + CD4 + ) and Th2 (IL-4) + CD4 + ) cell ratio ( Figure 9 The results showed that, compared with the PBMC-only group, the proportion of Th1 cells in the CAR-MSC group was significantly lower (p=0.0213) and significantly lower than that in the UTD-MSC group (p=0.0472); at the same time, the proportion of Th2 cells in the CAR-MSC group was significantly higher (p=0.0376) and also significantly higher than that in the UTD-MSC group (p=0.0278). These results indicate that CAR-MSCs can inhibit Th1 cell differentiation and increase the proportion of Th2 cells, downregulate the Th1 / Th2 ratio, change the Th1 / Th2 balance, and reshape the shift of T cells towards immune tolerance, suggesting that they have the potential to alleviate T cell-mediated inflammatory responses.
[0166] 5. CAR-MSCs inhibit the killing ability of CAR-T cells. To further evaluate the regulatory role of CAR-MSCs in the activation and effector function of CAR-T cells, this experiment established an in vitro co-culture system and an in vivo tumor-bearing animal model to verify the effect of CAR-MSCs on the anti-tumor function of CD19 CAR-T cells (CAR19).
[0167] 5.1 CAR-MSCs inhibit the tumor-killing activity and effector cytokine secretion of CAR-T cells. CAR-MSCs were cultured at 37℃ and 5% CO2 at a rate of 1×10⁻⁶. 4 Seeds were placed into 48-well plates at a density of 3 × 10⁶ cells / well. When the cell aggregation degree reached 90%, target cells expressing green fluorescent protein (Raji cells) were added at a density of 3 × 10⁶ cells / well. 4 The cells were seeded at a density of 1 / 1 well into 48-well plates, and then T cells were added to the 48-well plates for co-culture at an effector-to-target ratio of 1:1 (denoted as the CAR-MSC group). The following groups were used as controls: those with no transduced mesenchymal cells (denoted as the UTD-MSC group), those without mesenchymal cells (denoted as the CAR19+Raji group), and those with only CAR19-T cells cultured alone (denoted as the CAR19 olny group). After 24 hours, the functional indicators were detected by flow cytometry.
[0168] The results show that ( Figure 10 Compared to the CAR19+Raji group, the relative lysis rate of CAR-T cells against target cells was significantly reduced in both the UTD-MSC group and the CAR-MSC group; among them, the inhibitory effect of the CAR-MSC group on CAR-T killing activity was significantly stronger than that of the UTD-MSC group (p=0.0048). These results indicate that CAR-MSCs can effectively inhibit the CAR-T cell-mediated killing activity against CD19+Raji. + It has the ability to kill tumor cells, and its inhibitory efficacy is better than that of untransduced mesenchymal cells.
[0169] Simultaneously, flow cytometry analysis of intracellular cytokine expression results showed that ( Figure 11Compared to the CAR19-only group, the expression levels of interferon-γ (IFN-γ) and interleukin-2 (IL-2) in CAR-T cells of the CAR19+Raji group were significantly increased after target cell stimulation. After the addition of mesenchymal cells, the median fluorescence intensity (MFI) of IFN-γ (p=0.0045) and IL-2 (p=0.0005) in CAR-T cells of the CAR-MSC group was significantly reduced, and its inhibitory effect was significantly stronger than that of the UTD-MSC group. These results indicate that CAR-MSCs can significantly inhibit the excessive secretion of pro-inflammatory effector factors after CAR-T cell activation.
[0170] The effect of CAR-MSCs on the effector function of CAR-T cells was evaluated by detecting the expression of the degranulation marker CD107a. Figure 12 The results showed that CD8 in each treatment group + and CD4 + There was no significant difference in the proportion of CD107a positive CAR-T cells (ns).
[0171] The above in vitro experimental results show that CAR-MSCs can reduce the killing activity of CAR-T cells against tumor cells while inhibiting the excessive secretion of pro-inflammatory factors such as IFN-γ and IL-2 by CAR-T cells, suggesting that CAR-MSCs can effectively regulate the over-activation state of CAR-T cells.
[0172] 5.2 CAR-MSCs inhibit the in vivo anti-tumor function of CAR-T cells A Burkitt lymphoma model was established using healthy female NOG mice aged 6–8 weeks (purchased from Vital River Laboratory Animal Technology Co., Ltd., Beijing). On day-3, mice were injected with 1×10⁻⁶ mice via the tail vein. 6 Raji cells were administered regularly to monitor tumor growth. On Day 0, patients were randomly assigned to three groups: CAR19 only, UTD-MSC, and CAR-MSC. Each group received a tail vein injection of 2 × 10⁶ Raji cells. 6 10 CAR-T cells were injected simultaneously into the UTD-MSC group and the CAR-MSC group, respectively. 6 The mice were injected with the corresponding MSC cells every week, and the tumor burden was monitored by bioluminescence imaging to evaluate the survival of the mice.
[0173] Bioluminescence imaging results showed that ( Figure 13Compared with the CAR19 only group and the UTD-MSC group, the tumor burden (Total Flux) in the CAR-MSC group mice increased significantly over time (p=0.0354, p=0.0428), suggesting that CAR-MSC infusion weakened the ability of CAR-T cells to inhibit tumors in vivo.
[0174] Survival analysis results showed that ( Figure 14 The median survival of mice in the CAR-MSC group was significantly shorter than that in the CAR19 only group (p=0.0126) and the UTD-MSC group (p=0.0042), which is consistent with the tumor burden monitoring results mentioned above, further confirming that CAR-MSC can inhibit the anti-tumor function of CAR-T cells in vivo.
[0175] The results of the changes in body weight of mice in each group showed that ( Figure 15 There were no significant differences in body weight changes among the groups (ns), indicating that under the experimental conditions described, CAR-MSC infusion did not cause significant systemic toxicity and had good in vivo safety.
[0176] Peripheral blood flow cytometry results showed ( Figure 16 On Day 15 and Day 43, peripheral blood CD45 in the CAR-MSC group + CD3 + The number of T cells was significantly lower in the CAR19-only group and also significantly lower in the UTD-MSC group on day 43 (p=0.0483). Subgroup analysis showed that the CD4 count in the CAR-MSC group was significantly lower. + The absolute number of CAR-T cells was significantly lower than that of the UTD-MSC group. This phenomenon is related to the fact that OX40 is mainly expressed on CD4. + The consistent characteristics of T cells suggest that CAR-MSCs preferentially inhibit CD4 through OX40 targeting. + In vivo expansion of CAR-T cells.
[0177] Based on the above in vitro and in vivo experimental results, this experiment confirms that CAR-MSCs can significantly inhibit the activation and effector function of CAR-T cells, mainly by reducing the inhibitory effect of CAR-T cells on CD19 at the in vitro level. + The CAR-MSCs enhance the tumor-killing activity of CAR-T cells and inhibit the excessive secretion of pro-inflammatory factors such as IFN-γ and IL-2. Furthermore, they weaken the tumor-controlling ability of CAR-T cells at in vivo levels and inhibit their proliferation, exerting these regulatory effects without causing significant systemic toxicity. Moreover, in multiple indicators, the regulatory efficacy of CAR-MSCs is significantly superior to that of untransduced mesenchymal cells (UTD-MSCs), indicating that the introduction of the CAR structure can enhance the targeted inhibition ability of mesenchymal cells against the overactivation of CAR-T cells.
[0178] 6. CAR-MSC therapy in humanized aGVHD mouse model A 6-8 week old healthy female NOG mice (purchased from Vital River Laboratory Animal Technology Co., Ltd., Beijing) were used to establish an aGVHD model. X-ray irradiation of 100 cGy was administered on Day-1, and 5 × 10⁵ cGy was injected via the tail vein on Day 0. 6 PBMC cells. Animals were randomly divided into three groups according to body weight: PBMC only group, UTD-MSC group, and CAR-MSC group. Each group was injected with 1×10⁻⁶ PBMC cells via the tail vein. 6 Mice were injected with corresponding MSC cells every week, and their GVHD scores, body weight, survival status and peripheral blood T cell counts were dynamically monitored. Histopathological analysis was performed on Day 29.
[0179] 6.1 CAR-MSCs improve clinical symptoms and prolong survival in GVHD GVHD scoring monitoring results show that ( Figure 17 The GVHD scores of mice in the CAR-MSC group were significantly lower than those in the PBMC-only group and the UTD-MSC group throughout the observation period, while there was no significant difference between the UTD-MSC group and the PBMC-only group. Weight monitoring results showed ( Figure 18 The CAR-MSC group mice experienced significantly less weight loss than the two control groups. Representative mouse appearance photographs show ( Figure 19 Mice in the PBMC-only group and the UTD-MSC group showed obvious signs of GVHD, such as prickle hair, emaciation, and kyphosis, while the signs were significantly improved in the CAR-MSC group. Survival analysis results showed that ( Figure 20 The median survival of mice in the CAR-MSC group was significantly longer than that in the UTD-MSC group and the PBMC only group, while there was no significant difference in survival between the UTD-MSC group and the PBMC only group.
[0180] 6.2 CAR-MSCs reduce target organ damage Histopathological analysis of lung tissue from Day 29 mice ( Figure 21 HE staining results showed that the lung tissues of the PBMC-only group and the UTD-MSC group exhibited significant inflammatory cell infiltration and tissue structure destruction, while the lung tissue structure of the CAR-MSC group remained intact, and inflammatory cell infiltration was significantly reduced. CD3 immunohistochemical staining results showed that CD3 levels were significantly higher in the lung tissue of the CAR-MSC group. +The number of infiltrating T cells was significantly lower than that in the two control groups. Blinded pathological scoring showed that the lung injury score in the CAR-MSC group was significantly lower than that in the PBMConly group and the UTD-MSC group, while there was no significant difference between the two control groups.
[0181] 6.3 CAR-MSCs reduce the number of peripheral blood T cells and selectively inhibit OX40. + CD4 + T cells Flow cytometry was used to detect the number of peripheral blood T cells on Day 14 and Day 28. The results showed that ( Figure 22 ), CAR-MSC group CD45 + CD3 + The absolute number of T cells was significantly lower than that in the PBMC-only group and the UTD-MSC group at both time points, and both CD4+ and CD8+ T cells were significantly reduced.
[0182] Further examination was conducted to determine the expression of OX40 on the surface of peripheral blood T cells. Figure 23 The results showed that CD4 in the CAR-MSC group + The proportion of OX40-positive T cells was significantly lower in the PBMC-only group and the UTD-MSC group, while CD8... + The proportion of OX40-positive T cells did not differ significantly among the groups. Representative flow cytometry scatter plots further visualized the OX40 content in peripheral blood of the CAR-MSC group. + CD4 + The selectivity of the proportion of double-positive T cells decreased. These results demonstrate in vivo that CAR-MSCs can preferentially target and inhibit OX40. + CD4 + The therapeutic effect of T cells on aGVHD is intrinsically consistent with their CAR recognition structure and OX40 expression characteristics.
[0183] Based on the above in vivo experimental results, CAR-MSCs can effectively treat humanized aGVHD mouse models, mainly manifested in the improvement of GVHD clinical symptoms and body weight, the prolongation of survival, the reduction of inflammatory cell infiltration in target organs, and the enhancement of T cells, especially OX40 cells, in vivo. + CD4 + The selective reduction in the number of T cells was observed. The regulatory efficacy of the aforementioned indicators was significantly superior to that of UTD-MSCs, indicating that the introduction of the CAR structure endows mesenchymal cells with the ability to target and inhibit activated T cells, thereby enhancing its therapeutic efficacy against aGVHD.
[0184] 7. The 4-1BB co-stimulatory domain is an essential component for the function of CAR-MSCs. To identify the key intracellular signaling domains driving CAR-MSC function in the CAR structure, this study constructed four CAR-MSC variants containing different intracellular domains and systematically compared their functional differences in in vitro and in vivo models.
[0185] 7.1 Construction and identification of CAR-MSCs containing different intrasib domains Four CAR variants were constructed: a full-function construct (BBζ) containing both the complete 4-1BB and CD3ζ domains; a construct containing only the 4-1BB domain (4-1BB); a construct containing only the CD3ζ domain (CD3ζ); and a negative control construct (CD8TM) retaining only the CD8α transmembrane region without any intracellular signaling domains. Figure 24 Flow cytometry results showed that the CAR surface expression efficiency of the four constructs was comparable. Figure 25 This eliminates the interference of transduction efficiency differences on subsequent functional comparisons.
[0186] 7.2 Both BBζ and 4-1BB constructs exhibited strong protective effects in the in vivo aGVHD model. Using the same humanized aGVHD model as in Part 6 of this study, the disease progression of six groups of animals (PBMC only, UTD-MSC, BBζ, 4-1BB, CD3ζ, CD8TM) was compared.
[0187] Weight monitoring, GVHD score and survival analysis results showed ( Figure 26 Both the BBζ and 4-1BB groups showed strong protective effects, reducing weight loss, lowering clinical GVHD scores, and prolonging survival, which were superior to the other experimental groups overall. There was no significant difference in protective efficacy between the BBζ and 4-1BB groups.
[0188] Lung tissue pathology scoring results showed ( Figure 27 The protective effects of each construct showed a gradient consistent with clinical indicators. The BBζ and 4-1BB groups significantly reduced inflammatory cell infiltration and tissue damage, showing superior overall performance compared to the other constructs and the control group, suggesting that the presence of intracellular signaling domains is indispensable for maintaining in vivo protective effects. Liver tissue pathology results were consistent with lung tissue findings; the liver injury scores of the BBζ and 4-1BB groups were significantly lower than those of the other constructs and the control group. Figure 28 ).
[0189] 7.3 BBζ Construct Pair with OX40 + CD4 + The selective inhibition of T cells has the strongest effect. Peripheral blood T cell subset analysis results showed ( Figure 29 ), Day 17 and Day 27, CD3 of BBζ group and 4-1BB group+ The absolute number of T cells in the BBζ group was significantly lower than that in other groups, and the BBζ group showed a significant reduction in CD4+. + The inhibitory effect on T cells was stronger in the 4-1BB group than in the 4-1BB group. Both constructs, however, showed stronger inhibition of CD8. + The inhibitory activity of T cells is comparable.
[0190] Further testing of peripheral blood OX40 in each group + CD4 + The proportion of T cells, the results showed ( Figure 30 ), 4-1BB group and BBζ group OX40 + CD4 + The proportion of T cells was at a low level, significantly lower than that of other construction groups and the control group, and the OX40 of each group was low. + CD8 + There was no significant difference in the proportion of T cells (ns), and OX40 was mainly expressed on CD4. + The characteristics of T cells were consistent. The gradient ranking among the groups was highly consistent with lung injury scores and survival outcomes, further supporting the direct correlation between the in vivo efficacy of CAR-MSCs and their degree of OX40 targeting.
[0191] Simultaneously, mesenchymal cell surface markers were identified in five MSC constructs (UTD-MSC, BBζ, 4-1BB, CD3ζ, and CD8TM). Flow cytometry results showed ( Figure 31 Each construct expressed high levels of CD73, CD90, and CD105, and low levels of CD14, CD34, and CD45. There were no statistically significant differences (ns) among the groups, which met the ISCT criteria for mesenchymal cell identification.
[0192] Based on the combined results of in vitro and in vivo experiments, this study confirms that the 4-1BB co-stimulatory domain is an essential component for CAR-MSCs to exert their targeted immunosuppressive function. CAR-MSCs containing the complete BBζ domain showed improved T cell suppression in vitro, increased GVHD score in vivo, prolonged survival, protection against lung and liver pathological changes, and enhanced OX40 levels. + CD4 + The 4-1BB and CD3ζ combination showed the best performance across all readout metrics, including selective T-cell inhibition. These results suggest that in the engineering strategy of introducing CAR structures into MSCs, the synergistic combination of 4-1BB and CD3ζ is a key design choice for achieving optimal immunomodulatory efficacy.
[0193] 8. Targeted homing and persistence of CAR-MSCs in vivo To evaluate the biodistribution characteristics of CAR-MSCs in vivo and their spatial relationship with target cells, this experiment was conducted in a humanized aGVHD model and an OX40 model. + Tracking the in vivo kinetics of luciferase-GFP double-labeled MSCs in the Jurkat tumor-bearing model.
[0194] 8.1 GVHD environment promotes accelerated clearance of CAR-MSCs Akaluc-GFP-labeled CAR-MSCs and UTD-MSCs (1×10⁻⁶ each) were used. 6 MSCs (injected via tail vein) were administered to humanized aGVHD model NOG mice. Following administration of AkaLumine, MSC survival was dynamically monitored via BLI on days 0, 2, 4, and 6 post-injection. Results showed ( Figure 32 The BLI signal decay rate in the CAR-MSC group was significantly faster than that in the UTD-MSC group (p=0.0009), suggesting that CAR-MSCs are cleared more quickly in vivo in the inflammatory microenvironment of GVHD.
[0195] 8.2 The GVHD inflammatory microenvironment, rather than the CAR structure itself, drives the accelerated clearance of CAR-MSCs. To clarify whether the aforementioned accelerated clearance is related to the CAR structure itself, this experimental case established an OX40 + The Jurkat tumor-bearing model was used as a control. 2 × 10⁻⁶ cells were injected via tail vein on Day 7. 5 OX40 + Jurkat cells, Day 0, infused with Akaluc-GFP-labeled CAR-MSCs or UTD-MSCs (1×10⁻⁶). 6 (Number), AkaLumine was dynamically tracked via BLI on Days 0, 2, and 4. The results show ( Figure 33 In this model, there was no significant difference in the BLI signal decay curves between CAR-MSCs and UTD-MSCs (p=0.3969). The difference in decay kinetics between the two models suggests that the accelerated clearance of CAR-MSCs in the GVHD model is not determined by the structural characteristics of the CAR molecule itself, but is more likely related to the systemic inflammatory microenvironment unique to GVHD, in which the retention of MSCs in the lungs and the activation of local inflammation after intravenous infusion are important influencing factors.
[0196] 8.3 CAR-MSCs selectively accumulate in GVHD target organs and co-localize with infiltrating T cells. Humanized aGVHD model mice were sacrificed on Day 14, and ex vivo organ BLI imaging was performed using DiR fluorescently labeled CAR-MSCs and UTD-MSCs to quantitatively analyze the relative distribution of MSCs in each organ. The results showed ( Figure 34 There was no significant difference in total fluorescence signal between the two groups (p=0.8744), but the relative fluorescence flux of CAR-MSCs in the liver (p=0.0449) and colon (p=0.0492) was significantly higher than that of UTD-MSCs, indicating that CAR-MSCs preferentially accumulate in the main target organs of GVHD.
[0197] In summary, CAR-MSCs exhibit a characteristic biodistribution pattern of lesion enrichment in vivo. They were cleared faster than UTD-MSCs in the aGVHD model, but this phenomenon was not observed in the Jurkat tumor-bearing model lacking systemic inflammation, suggesting that this accelerated clearance reflects the active participation of CAR-MSCs in the immune response within inflammatory lesions, rather than a stability defect caused by the CAR structure. The in vivo targeting and homing capabilities described above corroborate the therapeutic effects of CAR-MSCs discussed in Part 6, jointly supporting the core mechanism by which CAR engineering strategies enable MSCs to target and locate at sites of activated T cell aggregation, thereby maximizing their local immunomodulatory efficacy.
Claims
1. A chimeric antigen receptor that targets and activates T cells, characterized in that, From the N-terminus to the C-terminus, it comprises, in sequence: a signal peptide, an antigen recognition domain, a hinge region, a transmembrane domain, and an intracellular signal transduction domain; the amino acid sequence of the antigen recognition domain is shown in SEQ ID NO:
2.
2. The chimeric antigen receptor according to claim 1, characterized in that, The signal peptide includes the CD8α signal peptide; the coding sequence of the CD8α signal peptide is shown in SEQ ID NO:3, and the amino acid sequence is shown in SEQ ID NO:4; And / or, the coding sequence of the antigen recognition domain is as shown in SEQ ID NO:1; And / or, the hinge region includes a CD8α hinge region, a CD28 hinge region, an IgG1 Fc hinge region, or an IgG4 Fc hinge region; the coding sequence of the CD8α hinge region is shown in SEQ ID NO:5, and the amino acid sequence is shown in SEQ ID NO:6; the IgG4 Fc hinge region includes a short IgG4 Fc hinge region, a medium IgG4 Fc hinge region, or a long IgG4 Fc hinge region; the coding sequence of the short IgG4 Fc hinge region is shown in SEQ ID NO:20, and the amino acid sequence is shown in SEQ ID NO:21; the coding sequence of the medium IgG4 Fc hinge region is shown in SEQ ID NO:22, and the amino acid sequence is shown in SEQ ID NO:23; the coding sequence of the long IgG4 Fc hinge region is shown in SEQ ID NO:24, and the amino acid sequence is shown in SEQ ID NO:
25. And / or, the transmembrane domain includes a CD8α transmembrane domain, a CD28 transmembrane domain, a CD3ζ transmembrane domain, or a 4-1BB transmembrane domain; the coding sequence of the CD8α transmembrane domain is shown in SEQ ID NO:7, and the amino acid sequence is shown in SEQ ID NO:8; And / or, the intracellular signal transduction domain includes an activation domain and / or a co-stimulatory domain; the activation domain includes a CD3ζ activation domain; the coding sequence of the CD3ζ activation domain is shown in SEQ ID NO:11, and the amino acid sequence is shown in SEQ ID NO:12; The costimulation domains include one or more of the following: CD28 costimulation domain, 4-1BB costimulation domain, OX40 costimulation domain, ICOS costimulation domain, CD27 costimulation domain, and CD40 costimulation domain. The coding sequence of the 4-1BB co-stimulatory domain is shown in SEQ ID NO:9, and the amino acid sequence is shown in SEQ ID NO:10; The coding sequence of the CD28 co-stimulatory domain is shown in SEQ ID NO:26, and the amino acid sequence is shown in SEQ ID NO:
27.
3. A nucleic acid molecule, characterized in that, The nucleic acid molecule encodes the chimeric antigen receptor as described in any one of claims 1 to 2.
4. The nucleic acid molecule according to claim 3, characterized in that, The nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO:
13.
5. A recombinant expression vector, characterized in that, It includes the nucleic acid molecule described in any one of claims 3 to 4.
6. A mesenchymal cell, characterized in that, It comprises the nucleic acid molecule as described in any one of claims 3 to 4 or the recombinant expression vector as described in claim 5.
7. The method for preparing mesenchymal cells according to claim 6, characterized in that, include: The nucleic acid molecule according to any one of claims 3 to 4 or the recombinant expression vector according to claim 5 is introduced into primitive mesenchymal cells to obtain the mesenchymal cells.
8. The use of the mesenchymal cells of claim 6 in the preparation of products for the treatment and / or prevention of diseases related to abnormal or excessive activation of T cells.
9. The application according to claim 8, characterized in that, The T-cell abnormality or overactivation-related diseases include graft-versus-host disease, side effects caused by CAR-T therapy, autoimmune diseases, or organ transplant rejection; the side effects caused by CAR-T therapy include cytokine release syndrome.
10. A pharmaceutical composition, characterized in that, It comprises the mesenchymal cells as described in claim 6, and a pharmaceutically acceptable carrier.
